scholarly journals Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study

Critical Care ◽  
2008 ◽  
Vol 12 (4) ◽  
pp. R111 ◽  
Author(s):  
Andreas Link ◽  
Matthias Girndt ◽  
Simina Selejan ◽  
Ranja Rbah ◽  
Michael Böhm
Keyword(s):  
Renal Replacement Therapy ◽  
Pilot Study ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy

scholarly journals ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study)

2019 ◽  
Vol 48 (1) ◽  
pp. 60-66 ◽  
Author(s):  
Mauro Neri ◽  
Anna Lorenzin ◽  
Massimo de Cal ◽  
Alessandra Brendolan ◽  
Nicola Marchionna ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Pilot Study ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Treatment Duration ◽  
Fourth Generation ◽  
Average Percentage ◽  
Total Treatment Time ◽  
Total Treatment ◽  
Delivered Dose

Background: ACUsmart (Medica S.P.A., Italy) is a new-generation, continuous renal replacement therapy (CRRT) machine for critically ill patients with acute kidney injury. We designed a multicenter international pilot study to provide a description of outlines of the ACUsmart system, evaluation aspects of functionality, usability, and feasibility, discriminating reasons of possible treatment’s withdrawals or discontinuations and highlighting strong and weak points of the machine. Methods: Data of 23 CRRT (and 11 plasma exchange) treatments were collected from 4 intensive care units. Parameters such as treatment duration, downtime, delivered dose, and number and type of alarms were recorded. The general perception of the machine was quantified through the administration of a survey to each component of the evaluating staff. Results: A total treatment time of 447 h was carried with ACUsmart. Eleven continuous veno-venous hemofiltration, 4 continuous veno-venous hemodialysis , and 8 continuous veno-venous hemodiafiltration were performed. The average percentage of net treatment duration with respect to total treatment duration was 92.37%. The mean prescribed dose and delivered dose were 26.33 and 24.10 mL/kg/h, respectively. In general, the machine was rated by users involved as practical and easy to use, although few components need to be slightly improved. Conclusion: ACUsmart is a new multifunctional machine that meets most of the features required in a fourth-generation CRRT equipment.

scholarly journals Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy—A Pilot Study

Renal Failure ◽  
2007 ◽  
Vol 29 (3) ◽  
pp. 271-277 ◽  
Author(s):  
Jürgen Birnbaum ◽  
Claudia D. Spies ◽  
Edda Klotz ◽  
Ortrud Vargas Hein ◽  
Stanislao Morgera ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Pilot Study ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy

scholarly journals The Administration of Ciprofloxacin During Continuous Renal Replacement Therapy: Pilot Study

ASAIO Journal ◽  
2009 ◽  
Vol 55 (3) ◽  
pp. 243-245 ◽  
Author(s):  
Mineji Hayakawa ◽  
Itaru Fujita ◽  
Ken Iseki ◽  
Satoshi Gando
Keyword(s):  
Renal Replacement Therapy ◽  
Pilot Study ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy

scholarly journals Pilot Study of the Pharmacokinetics of Cefotaxime in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy

2016 ◽  
Vol 60 (6) ◽  
pp. 3587-3590 ◽  
Author(s):  
Joost B. Koedijk ◽  
Corinne G. H. Valk-Swinkels ◽  
Tom A. Rijpstra ◽  
Daan J. Touw ◽  
Paul G. H. Mulder ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Renal Replacement Therapy ◽  
Pilot Study ◽  
Plasma Level ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Plasma Levels ◽  
Kidney Injury

The objective of this study was to describe the pharmacokinetics of cefotaxime (CTX) in critically ill patients with acute kidney injury (AKI) when treated with continuous renal replacement therapy (CRRT) in the intensive care unit (ICU). This single-center prospective observational pilot study was performed among ICU-patients with AKI receiving ≥48 h concomitant CRRT and CTX. CTX was administered intravenously 1,000 mg (bolus) every 6 h for 4 days. CRRT was performed as continuous venovenous hemofiltration (CVVH). Plasma concentrations of CTX and its active metabolite desacetylcefotaxime (DAC) were measured during CVVH treatment. CTX plasma levels and patient data were used to construct concentration-time curves. By using this data, the duration of plasma levels above 4 mg/liter (four times the MIC) was calculated and analyzed. Twenty-seven patients were included. The median CTX peak level was 55 mg/liter (range, 19 to 98 mg/liter), the median CTX trough level was 12 mg/liter (range, 0.8 to 37 mg/liter), and the median DAC plasma level was 15 mg/liter (range, 1.5 to 48 mg/liter). Five patients (19%) had CTX plasma levels below 4 mg/liter at certain time points during treatment. In at least 83% of the time any patient was treated with CTX, the CTX plasma level stayed above 4 mg/liter. A dosing regimen of 1,000 mg of CTX given four times daily is likely to achieve adequate plasma levels in patients with AKI treated with CVVH. Dose reduction might be a risk for suboptimal treatment.

Sign in / Sign up

Export Citation Format

Share Document